EBSEmergent BioSolutions Inc.

NYSE emergentbiosolutions.com


$ 7.50 $ 0.43 (6.09 %)    

Tuesday, 02-Jul-2024 15:59:56 EDT
QQQ $ 486.52 $ 5.06 (1.05 %)
DIA $ 393.25 $ 1.83 (0.47 %)
SPY $ 548.30 $ 3.67 (0.67 %)
TLT $ 90.61 $ 0.70 (0.78 %)
GLD $ 215.57 $ -0.01 (0 %)
$ 7.49
$ 7.14
$ 7.49 x 195
$ 7.51 x 400
$ 7.14 - $ 8.24
$ 1.42 - $ 8.29
4,423,263
na
390.98M
$ 1.11
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-01-2024 03-31-2024 10-Q
2 03-08-2024 12-31-2023 10-K
3 12-11-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-01-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-01-2022 06-30-2022 10-Q
9 04-28-2022 03-31-2022 10-Q
10 02-25-2022 12-31-2021 10-K
11 11-05-2021 09-30-2021 10-Q
12 07-30-2021 06-30-2021 10-Q
13 04-30-2021 03-31-2021 10-Q
14 02-19-2021 12-31-2020 10-K
15 11-06-2020 09-30-2020 10-Q
16 07-31-2020 06-30-2020 10-Q
17 05-01-2020 03-31-2020 10-Q
18 02-25-2020 12-31-2019 10-K
19 11-07-2019 09-30-2019 10-Q
20 08-02-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 02-22-2019 12-31-2018 10-K
23 11-02-2018 09-30-2018 10-Q
24 08-03-2018 06-30-2018 10-Q
25 05-04-2018 03-31-2018 10-Q
26 02-23-2018 12-31-2017 10-K
27 11-03-2017 09-30-2017 10-Q
28 08-04-2017 06-30-2017 10-Q
29 05-05-2017 03-31-2017 10-Q
30 02-28-2017 12-31-2016 10-K
31 11-09-2016 09-30-2016 10-Q
32 08-05-2016 06-30-2016 10-Q
33 05-06-2016 03-31-2016 10-Q
34 02-29-2016 12-31-2015 10-K
35 11-06-2015 09-30-2015 10-Q
36 08-06-2015 06-30-2015 10-Q
37 05-08-2015 03-31-2015 10-Q
38 03-06-2015 12-31-2014 10-K
39 11-10-2014 09-30-2014 10-Q
40 08-08-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-is-vaccine-maker-emergent-biosolutions-stock-trading-higher-on-tuesday

Emergent BioSolutions has secured over $250 million in contract modifications from the ASPR at the U.S. Department of Health an...

 benchmark-reiterates-buy-on-emergent-biosolutions-maintains-8-price-target

Benchmark analyst Robert Wasserman reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $8 price target.

 benchmark-reiterates-buy-on-emergent-biosolutions-maintains-8-price-target

Benchmark analyst Robert Wasserman reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $8 price target.

 benchmark-reiterates-buy-on-emergent-biosolutions-maintains-8-price-target

Benchmark analyst Robert Wasserman reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $8 price target.

 what-is-going-on-with-emergent-biosolutions-shares

On Thursday prior to the market open, Emergent BioSolutions announced it entered into a definitive agreement with Bora to sell ...

 benchmark-maintains-buy-on-emergent-biosolutions-raises-price-target-to-8

Benchmark analyst Robert Wasserman maintains Emergent BioSolutions (NYSE:EBS) with a Buy and raises the price target from $5...

 emergent-biosolutions-to-sell-baltimore-camden-manufacturing-site-to-bora-pharma-for-30m

 Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into a definitive agreement to sell its drug product...

 emergent-biosolutions-reports-blockbuster-q1-results-raises-guidance-whats-going-on-with-the-stock

Emergent reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of losses of 83 cents by 171....

Core News & Articles
Market-Moving News May 2nd
05/02/2024 12:39:37

ALLR: 151% | Allarity Therapeutics shares are trading higher after the company announced that Stenoparib shows a clear clinical...